Stockreport

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 [Yahoo! Finance]

Profusa, Inc.  (PFSA) 
PDF potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen BERKELEY, Calif, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa [Read more]